<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367763">
  <stage>Registered</stage>
  <submitdate>23/01/2015</submitdate>
  <approvaldate>1/04/2015</approvaldate>
  <actrnumber>ACTRN12615000305527</actrnumber>
  <trial_identification>
    <studytitle>Comparison of immune response of fractional doses, administered intradermally vs. full doses administered intramuscularly of inactivated poliovirus vaccine (IPV) in male adults in Camaguey, Cuba.</studytitle>
    <scientifictitle>Comparison of immune response of fractional doses, administered intradermally vs. full doses administered intramuscularly of inactivated poliovirus vaccine (IPV) in male adults in Camaguey, Cuba.</scientifictitle>
    <utrn>U1111-1166-1588 </utrn>
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Poliomyelitis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Epidemiology</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Subjects will receive two doses of intradermal injection of Salk IPV (20:32:64 DU/dose) 0.1 ml, 1 month apart</interventions>
    <comparator>Controls will recieve two doses of Salk IPV (20:32:64 DU/dose) 0.5 ml intramuscularly, 1 month apart</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint is a boosting immune response, defined as the proportion (%) of subjects with a change from seronegative (reciprocal titer of less than 1:8 dilution) to seropositive after vaccine administration or an increase of four times or more in reciprocal titer for seropositive subjects (those with baseline reciprocal titer greater than 1:8)</outcome>
      <timepoint>At day 0 (baseline; visit 1), day 7 (after single dose; visit 2), day 28 (after single dose; visit 3) and day 56 (after two doses; visit 4)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The safety will be assessed by the number and intensity of local (e.g. redness, swelling ,infection) and systemic adverse reactions (e.g. fever)</outcome>
      <timepoint>Subjects will be observed during the first 60 minutes after vaccination in order to record the occurrence of acute reactions. 
A diary will be given to each subject for reporting of adverse events in the first seven days after vaccination. Follow-up is done at 24 hours, 48 hours, 72 hours, and 7 days after vaccination</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects have to fulfill all of the following criteria:
*Males age 18 to 30, inclusive at the time of enrollment; and
*in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator; and 
*must have received polio vaccinations with at least one dose of OPV according to the Cuban National Immunization Program as a child; and
*willing to sign an informed consent form.
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>30</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>The exclusion criteria for vaccination are 
* IPV or OPV booster dose after the age of 12 years; or
* Known or suspected exposure to wild poliovirus
* known or suspected allergy against any of the vaccine components; or
* history of unusual or severe reactions to any previous vaccination; or
* known or suspected disease or use of medication that may influence the immune system; or
* known or suspected immune deficiency, and/or known HIV infection; or
* systemic treatment with corticosteroids or immunosuppressant within one month before screening or during the study; or
* administration of plasma (including immunoglobulins) or blood products three months prior to the study during the study; or
* blood donation within one month before screening; or
* any vaccination within three months before screening and during the study until the last visit; or
* history of any neurological disorder including epilepsy or febrile seizures; or
*evidence of excessive alcohol use or drug use; or
*any infectious disease; or
*participation in another clinical trial within three months before enrollment.
*Bleeding disorders or the usage of anticoagulants.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>4/12/2014</anticipatedstartdate>
    <actualstartdate>4/12/2014</actualstartdate>
    <anticipatedenddate>8/01/2015</anticipatedenddate>
    <actualenddate>8/01/2015</actualenddate>
    <samplesize>600</samplesize>
    <actualsamplesize>534</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Cuba</country>
      <state>Camaguey</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>World Health Organization</primarysponsorname>
    <primarysponsoraddress>Avenue Appia 20
Geneva 
CH-1211</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>World Health Organization</fundingname>
      <fundingaddress>Avenue Appia 20
Geneva 
CH-1211</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Instituto Pedro Kouri (IPK) 
</othercollaboratorname>
      <othercollaboratoraddress>Marianao 13, Ciudad de La Habana</othercollaboratoraddress>
      <othercollaboratorcountry>Cuba</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Provincial Center for Health, Epidemiology and Microbiology (CPHEM), Camaguey</othercollaboratorname>
      <othercollaboratoraddress>Cisneros 203, Camaguey</othercollaboratoraddress>
      <othercollaboratorcountry>Cuba</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To demonstrate the non-inferiority of boosting immune responses after administration of one and two intradermal IPV doses compared with one and two intramuscular IPV doses in healthy adults with history of vaccination with at least one dose of OPV.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>WHO Research Ethics Review Committee (WHO ERC)</ethicname>
      <ethicaddress>Avenue Appia, 20
CH-1211 Geneva 27</ethicaddress>
      <ethicapprovaldate>7/04/2014</ethicapprovaldate>
      <hrec>RPC635</hrec>
      <ethicsubmitdate>29/11/2013</ethicsubmitdate>
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>IPK Ethics Committee</ethicname>
      <ethicaddress>P.O. Box: 601 Marianao 13
Habana</ethicaddress>
      <ethicapprovaldate>14/01/2014</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>28/11/2013</ethicsubmitdate>
      <ethiccountry>Cuba</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Provincial Center for Health, Epidemiology and Microbiology (CPHEM), Camaguey IRB</ethicname>
      <ethicaddress>Cisneros 203, Camaguey</ethicaddress>
      <ethicapprovaldate>20/11/2014</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>18/11/2014</ethicsubmitdate>
      <ethiccountry>Cuba</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Sonia Resik</name>
      <address>Instituto de Medicina Tropical "Pedro Kour√≠" (IPK)
P.O. Box: 601 Marianao 13
Habana</address>
      <phone>+53 7 2553550</phone>
      <fax />
      <email>sresik@ipk.sld.cu</email>
      <country>Cuba</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Sonia Resik</name>
      <address>Instituto de Medicina Tropical "Pedro Kouri" (IPK)
P.O. Box: 601 Marianao 13
Habana</address>
      <phone>+53 7 2553550</phone>
      <fax />
      <email>sresik@ipk.sld.cu</email>
      <country>Cuba</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Sonia Resik</name>
      <address>Instituto de Medicina Tropical "Pedro Kouri" (IPK)
P.O. Box: 601 Marianao 13
Habana</address>
      <phone>+53 7 2553550</phone>
      <fax />
      <email>sresik@ipk.sld.cu</email>
      <country>Cuba</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>